H.C. Wainwright raised the firm’s price target on Eton Pharmaceuticals (ETON) to $15 from $11 and keeps a Buy rating on the shares after the company announced the acquisition of the U.S. rights to Amglidia.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETON: